PCM
TRIB

Prelude Capital Management’s Trinity Biotech TRIB Stock Holding History

Prelude Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-471
Closed -$1.29M – 2150
2014
Q3 		$1.29M Buy
+471
New +$1.53M 0.18% 123
2014
Q1 		– Sell
-67
Closed -$251K – 2105
2013
Q4 		$251K Buy
+67
New +$241K 0.04% 557
2013
Q3 		– Sell
-67
Closed -$169K – 1835
2013
Q2 		$169K Buy
+67
New +$167K 0.04% 480

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Prelude Capital Management's TRIB Position: Q2 2017 in Review

Prelude Capital Management sold out of Trinity Biotech (TRIB) in Q2 2017, closing a stake of 106 shares — an estimated $95K sold.

Prelude Capital Management first reported a position in TRIB in Q2 2013 and held it in 14 quarters. The position peaked at $1.96M in Q2 2014. 56 funds tracked by Wall St. Rank hold TRIB as of Q2 2017.

  • Prelude Capital Management reported no remaining Trinity Biotech position as of Q2 2017 after selling out during the quarter.
  • Prelude Capital Management sold 106 Trinity Biotech shares in Q2 2017, an estimated $95K.
  • Prelude Capital Management first reported a position in Trinity Biotech in Q2 2013 and held it in 14 quarters.
  • Prelude Capital Management's Trinity Biotech position peaked at $1.96M in Q2 2014.
  • 56 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2017.

Based on Prelude Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.